This IDC study incorporates survey data and in-depth interviews from thought
leaders in the fields of genomics, genetics, bioinformatics, and technology
development. The panel consists of CEOs/presidents and chief scientific officers
(CSOs) from life science technology companies, directors and lead scientists
from pharmaceutical and biotechnology companies, executives and directors from
information technology and bioinformatic companies, senior faculty from top-tier
academic and research institutes, directors and scientists from large DNA
sequencing facilities, plus partners of venture capital firms investing in life
science companies.
This document combines the qualitative data gathered from interviews with the
quantitative survey results to formulate insights and actions for IT hardware
and software vendors, life science platform/equipment developers,
pharmaceutical/biotechnology companies, and companies developing genomic-based
technologies. Some of questions answered are:
- What advancements in life science and healthcare will occur as the cost of
sequencing a human genome declines?
- What are the price points at which DNA sequencing will become part of drug
discovery, clinical trials, and personalized medicine?
- Which markets will adopt DNA sequencing technologies at each declining
price point?
- How long will it take to develop a faster and cheaper DNA sequencing
technology, and what are the major technical issues?
- What are the bioinformatic issues for ultra-high-throughput DNA
sequencing, and what components of the IT infrastructure will require new
solutions?
- Who are the new companies developing DNA sequencing technologies, and how
will the life science and DNA sequencing market react as the cost declines?
Faster and cheaper DNA sequencing technologies have the potential to
revolutionize science and medicine. Zachary Zimmerman, Ph.D., of Life Science
Insights, an IDC company states, "Several start-up companies are trying to
develop new, disruptive DNA sequencing technologies. Many see the DNA sequencing
market poised for dramatic growth as personalized medicine becomes a reality and
as pharmaceutical companies attempt to reduce drug development costs and improve
clinical trial successes by utilizing genomic data to segment the population
into specific cohorts."
View Cart
